BR112022004723A2 - Formulações de insulina e glucagon injetáveis por via subcutânea e métodos de administração - Google Patents

Formulações de insulina e glucagon injetáveis por via subcutânea e métodos de administração

Info

Publication number
BR112022004723A2
BR112022004723A2 BR112022004723A BR112022004723A BR112022004723A2 BR 112022004723 A2 BR112022004723 A2 BR 112022004723A2 BR 112022004723 A BR112022004723 A BR 112022004723A BR 112022004723 A BR112022004723 A BR 112022004723A BR 112022004723 A2 BR112022004723 A2 BR 112022004723A2
Authority
BR
Brazil
Prior art keywords
methods
administration
injectable insulin
subcutaneously injectable
formulations
Prior art date
Application number
BR112022004723A
Other languages
English (en)
Inventor
A Rhodes Christopher
Lawrence D'souza
S Steiner Solomon
Original Assignee
Cass Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cass Pharmaceuticals Inc filed Critical Cass Pharmaceuticals Inc
Publication of BR112022004723A2 publication Critical patent/BR112022004723A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

formulações de insulina e glucagon injetáveis por via subcutânea e métodos de administração. a presente invenção refere-se a formulações de insulina injetáveis por via subcutânea de ação ultrarrápida, bem como formulações de insulina e glucagon injetáveis por via subcutânea estabilizadas, além de sistemas de injeção e métodos de tratamentos e uso dos mesmos.
BR112022004723A 2019-09-17 2020-09-16 Formulações de insulina e glucagon injetáveis por via subcutânea e métodos de administração BR112022004723A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962901408P 2019-09-17 2019-09-17
PCT/US2020/051111 WO2021055505A2 (en) 2019-09-17 2020-09-16 Subcutaneously injectable insulin and glucagon formulations and methods of administration

Publications (1)

Publication Number Publication Date
BR112022004723A2 true BR112022004723A2 (pt) 2022-06-14

Family

ID=72709853

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022004723A BR112022004723A2 (pt) 2019-09-17 2020-09-16 Formulações de insulina e glucagon injetáveis por via subcutânea e métodos de administração

Country Status (14)

Country Link
US (1) US20220354782A1 (pt)
EP (1) EP4031111A2 (pt)
JP (1) JP2022549201A (pt)
KR (1) KR20220066317A (pt)
CN (1) CN114980860A (pt)
AU (1) AU2020351154A1 (pt)
BR (1) BR112022004723A2 (pt)
CA (1) CA3153645A1 (pt)
CL (1) CL2022000617A1 (pt)
CO (1) CO2022002866A2 (pt)
IL (1) IL291451A (pt)
MX (1) MX2022002894A (pt)
PE (1) PE20220953A1 (pt)
WO (1) WO2021055505A2 (pt)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6428771B1 (en) 1995-05-15 2002-08-06 Pharmaceutical Discovery Corporation Method for drug delivery to the pulmonary system
EP2280021B1 (en) * 1999-06-29 2016-02-17 MannKind Corporation Pharmaceutical formulations comprising insulin complexed with a diketopiperazine
US10350354B2 (en) 2007-06-21 2019-07-16 Roche Diagnostics Operations, Inc. Device and method for preventing hypoglicemia
EP4159114B1 (en) 2007-10-09 2024-04-10 DexCom, Inc. Integrated insulin delivery system with continuous glucose sensor
DK2379511T3 (en) * 2008-12-29 2015-01-12 Mannkind Corp Substituted diketopiperazinanaloger for use as pharmaceutical management funds
US10188325B2 (en) 2012-03-09 2019-01-29 Rinat O. Esenaliev Wearable, noninvasive glucose sensing methods and systems
US10307464B2 (en) * 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
US10279106B1 (en) 2014-05-08 2019-05-07 Tandem Diabetes Care, Inc. Insulin patch pump
AR102869A1 (es) * 2014-12-16 2017-03-29 Lilly Co Eli Composiciones de insulina de rápida acción
WO2017124102A1 (en) 2016-01-14 2017-07-20 North Carolina State University Glucose responsive insulin delivery compositions and methods

Also Published As

Publication number Publication date
WO2021055505A3 (en) 2021-05-06
WO2021055505A2 (en) 2021-03-25
KR20220066317A (ko) 2022-05-24
IL291451A (en) 2022-05-01
CN114980860A (zh) 2022-08-30
JP2022549201A (ja) 2022-11-24
PE20220953A1 (es) 2022-06-07
CL2022000617A1 (es) 2022-10-28
MX2022002894A (es) 2022-06-16
AU2020351154A1 (en) 2022-03-31
US20220354782A1 (en) 2022-11-10
CA3153645A1 (en) 2021-03-25
CO2022002866A2 (es) 2022-07-08
EP4031111A2 (en) 2022-07-27

Similar Documents

Publication Publication Date Title
MX2013004406A (es) Tratamiento de diabetes mellitus usando inyecciones de insulina administradas con intervalos variables de inyeccion.
MX2023000320A (es) Metodos para modular los niveles de farmaco en plasma mediante el uso de eritrohidroxibupropion.
BR112016016290A2 (pt) Composições farmacêuticas de insulina de ação rápida, conjunto de infusão, sistema de conjunto de infusão e usos de análogos monoméricos ou diméricos de insulina
MX2021012050A (es) Formulaciones de proteinas liquidas que contienen agentes reductores de viscosidad.
EA201692159A1 (ru) Композиция для лечения диабета, содержащая конъюгат на основе аналога инсулина длительного действия и конъюгат на основе аналога инсулинотропного пептида длительного действия
CO2018000196A2 (es) Agente terapéutico para tratar el síndrome de hunter y método de tratamiento
EA201591987A1 (ru) Лечение злокачественной опухоли дигидропиразинопиразинами
MX2019007779A (es) Metodo cosmetico para el tratamiento o reduccion de paniculopatia edemato-fibroesclerotica (pefe).
BR112017014994A2 (pt) formulação em pó nasal para o tratamento de hipoglicemia
MX2016004257A (es) Composiciones oftalmicas basadas en epinefrina para la administracion intraocular y metodos para su frabricacion.
PH12015501931A1 (en) Treatment of diabetes mellitus by long-acting formulations of insulins
MD20140123A2 (ro) Agenţi terapeutici optimizaţi pentru administrare subcutanată
FR3036289B1 (fr) Dispositif d'injection de produit injectable comportant une canule coulissant dans une aiguille et systeme utilisant un tel dispositif
BR112022004723A2 (pt) Formulações de insulina e glucagon injetáveis por via subcutânea e métodos de administração
BR112013010345A2 (pt) tratamento de diabetes melitus usando as injeções de insulina administradas com intervalos de variação da injeção
MX2018007377A (es) Composicion de acido hialuronico para inyecciones en el pene.
SG10201803802YA (en) Sesame oil based injection formulations
PH12017501005A1 (en) Injectable formulations of paracetamol
RU2012123182A (ru) Способ коррекции психического состояния пациентов и антиоксидантого статуса при органическом расстройстве личности
AR103461A1 (es) Método de uso de la respuesta al anticuerpo anti-acetato de glatirámero
RU2013143983A (ru) Способ коррекции иммунной недостаточности у инфицированного вирусом лейкоза крупного рогатого скота
UA130145U (uk) Спосіб корекції анемічного синдрому в спортивних коней
SG10201809418VA (en) New administration routes of insulin, insulin analogs or derivatives of insulin
RU2012156689A (ru) Способ лечения синдрома эндогенной интоксикации, обусловленного гиперпротеолизом
RU2013119140A (ru) Способ лечения вегетососудистой дистонии у детей и подростков